This pilot, multi center study will establish the effectiveness of Given PillCam® Platform with the PillCam® Colon 2 Capsule as demonstrated by the identification of subjects with polyps, compared to standard colonoscopy.

This study will also use to evaluate the administrative feasibility and data management of study design.

Inclusion Criteria:

1. Subject is between 50 - 75 years of age, and an appropriate candidate for polyp screening.
2. Subject received an explanation about the nature of the study and agrees to provide written informed consent.

Exclusion Criteria:

1. Subject has a history of colorectal cancer
2. Subjects with history of any positive colon assessment (including CT, colonoscopy, sigmoidoscopy etc.),
3. Subject with history of negative colon assessment (including CT, colonoscopy, sigmoidoscopy etc.) < 5 years.
4. Subject has a first degree relative diagnosed with colorectal cancer before the age of 60 years old or 2 (or more) first degree relatives diagnosed with colorectal cancer at any age.
5. Subject is suspected or diagnosed with familial adenomatous polyposis.
6. Subject is suspected or diagnosed with hereditary nonpolyposis colon cancer.
7. Subject is suspected or diagnosed with inflammatory bowel disease, or chronic ulcerative colitis or Crohn's disease.
8. Subject is suspected or diagnosed with hematochezia, melena, Fe deficiency anemia or any other rectal bleeding., including positive FOBT test of any variety
9. Subject is suspected or diagnosed with bowel obstruction.
10. Subject has dysphagia or any swallowing disorder.
11. Subject has congestive heart failure.
12. Subject has Diabetes.
13. Subject has had prior abdominal surgery of the gastrointestinal tract in the last 6 months or other uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.
14. Subject has a cardiac pacemaker or other implanted electro medical device.
15. Subject has any allergy or other known contraindication to the medications used in the study.
16. Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
17. Subject with any condition believed to have an increased risk for capsule retention such as intestinal tumors, radiation enteritis, and incomplete colonoscopies due to obstructions or NSAID enteropathy.
18. Subject with strictures, fistulas and/or chronic constipation.
19. Subject with history or clinical evidence of renal disease and/or previous clinically significant laboratory abnormalities of renal function parameters.
20. Subject with known gastrointestinal motility disorders.
21. Subject has known delayed gastric emptying.
22. Subject has any condition, which precludes compliance with study and/or device instructions.
23. Women who are either pregnant or nursing at the time of screening, or are of child-bearing potential and do not practice medically acceptable methods of contraception.
24. Subject suffers from life threatening conditions.
25. Subject currently participating in another clinical study.

Adverse events were collected and documented until the end of Colonoscopy procedure, which was scheduled 4-6 weeks after the PillCam Colon 2 CE procedure and was the end of the study.

This was a feasibility study, in accordance with the definition of a feasibility study within the ACT checklist. The feasibility study was used as preparation to study pivotal study number MA- 204 NCT01372878 which has results posted on CT.gov.